Community Health Navigator Program to Promote Cancer Screenings Among DDBHH People
Launched by GALLAUDET UNIVERSITY · Jul 2, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Study hypothesizes that the intervention that involves utilization of a DDBHH CHN will result in (i) DDBHH patients demonstrating greater adherence to screening compared to DDBHH patients who were assigned to the standard of care group , and (ii) higher patient-physician communication rating by DDBHH patients compared to DDBHH patients who were assigned to the standard of care group. Bilingual ASL-English measures (e.g., sociodemographics, cancer knowledge, patient-physician communication) will be administered to the participant at baseline data collection and again after the final data col...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of signed and dated informed consent form
- • Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of the study
- • Male or female at birth age 45-80yo or female at birth age 45-80yo; age-eligible according to screening criteria
- • Self-reported diagnosis of bilateral hearing loss at birth or prior to 13 years old (defined as "early deafness") and use ASL
- • Willingness to adhere to the CHN clinical trial regimen
- • Willingness to provide cancer screening verification documentation; this will be reviewed during the informed consent procedure
- • Access to necessary resources to support video-based communication
- • Non-adherent to one or more cancer screening guidelines for breast, lung, prostate, colon, cervical cancers will be those who reported not having had the appropriate recommended screenings within the past year to cancer screening questions in the HINTS-ASL survey
- Exclusion Criteria:
- • Presence of full ability to hear in one or both ears beyond 13 years of age
- • Younger or older than the age cutoff for the recommended cancer screening
- • Not capable of independently conducting the activities of daily living
- • In compliance with age- or risk-specific screening at the time of evaluation for study eligibility
- • Are currently undergoing cancer treatment or being evaluated for the presence of cancer at the time of evaluation for study eligibility
- • Will be engaged in more than 21 consecutive days of travel during the eleven-month study window
- • Knows other participants at baseline
About Gallaudet University
Gallaudet University, a premier institution dedicated to the education and advancement of individuals who are deaf and hard of hearing, serves as a clinical trial sponsor committed to enhancing healthcare outcomes within this unique population. Leveraging its expertise in linguistics, education, and communication access, Gallaudet University aims to conduct innovative research that addresses the specific health needs and disparities faced by deaf and hard of hearing individuals. By fostering collaboration among diverse stakeholders, including healthcare professionals, researchers, and community organizations, Gallaudet University strives to develop evidence-based interventions and improve health equity, ultimately contributing to the body of knowledge that informs best practices in clinical care for these populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Poorna Kushalnagar
Principal Investigator
Gallaudet University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported